Imazamethabenz-methyl

CAS: 81405-85-8

Ref. 3D-GDA40585

Produktinformation

• Name: Imazamethabenz-methyl
• Synonyme: 2-(4-Isopropyl-4-méthyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4-méthylbenzoate de méthyle - 2-(4-isopropyl-4-méthyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-méthylbenzoate de méthyle (1:1), 2-[4,5-Dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-4(or 5)-methylbenzoic acid methyl ester, Ac 222293, Assert, Assert 300, Benzoic acid, 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-4(or 5)-methyl-, methyl ester, Dagger, Dagger G, Imazamethabenz methyl ester, Imazamethabenz-Methyl, Methyl 2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzoate - methyl 2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-methylbenzoate (1:1), Methyl-2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzoat-methyl-2-(4-isopropyl-4-methyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-5-methylbenzoat(1:1), methyl 2-[4,5-dihydro-4-methyl-4-(1-methylethyl)-5-oxo-1H-imidazol-2-yl]-4(or 5)-methylbenzoate

Beschreibung

Imazamethabenz-methyl is a chemotherapeutic agent that has been shown to reduce the production of acid in the urine by inhibiting the enzyme fatty acid amide hydrolase. It has been shown to be clinically relevant for patients with atrial fibrillation, and is used as an adjuvant in cancer therapy. Imazamethabenz-methyl has also been found to inhibit de novo fatty acid synthesis and increase the glomerular filtration rate in rats. This drug is thought to have an effect on stem cells, cell factor, and dehydroascorbate reductase. Imazamethabenz-methyl blocks the activity of monoclonal antibodies responsible for myocardial infarction in mice.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 288.34 g/mol
• Formel: C₁₆H₂₀N₂O₃
• Reinheit: Min. 95%